| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1002 | |
| Phytochemical name or plant extracts | Evodiamine | |
| PMID | 25621054 | |
| Literature evidence | Evodiamine is extracted from a variety of traditional Chinese medicines, which has been reported to induce apoptosis in certain tumors, including cervical, prostate and breast cancer, however, its effect on oestosarcoma cells remains unclear. | |
| IUPAC name | (1S)-21-methyl-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,15,17,19-heptaen-14-one | |
| Phytochemicals’ class or type of plant extracts | Alkaloid | |
| Source of phytochemicals or plant Extracts | Evodia rutaecarpa | |
| Geographical availability | E. Asia - China to the Himalayas. | |
| Plant parts | Fruits | |
| Other cancers | Breast cancer, Cervical cancer, Skin cancer, Leukemia | |
| Target gene or protein | MMP9, uPA, uPAR, ERK, p38 MAPK, topo I, Bax, Bcl-2, Caspase 3, Survivin | |
| Gene or Protein evidence | In vitro, evodiamine inhibited cell migration and invasion abilities through downregulation of MMP-9, urokinase-type plasminogen activator (uPA) and uPAR expression. Moreover, evodiamine regulated p-ERK and p-p38 MAPK expression. Herein, we report using a scaffold-hopping approach to identify a series of novel polycyclic heterocyclic derivatives based on Evo as the topoisomerase I (Top1) inhibitor for the treatment of triple-negative breast cancer (TNBC), which is an aggressive subtype of breast cancer with limited treatment options. evodiamine downregulated the expression of Bcl-2, caspase-3 and survivin, and upregulated the expression of Bax in human osteosarcoma cells. | |
| Target pathways | ER-inhibitory pathway, aspase-dependent pathway, Ras/MEK/ERK pathway | |
| IC50 | NA | |
| Potency | These results demonstrate that evodiamine possesses antitumor activities via inhibition of cell migration and invasion, arrest of the cell cycle and induction of cell apoptosis in MDA-MB-231 cells. | |
| Cell line/ mice model | MDA-MB-231, MCF-7, A375-S2, HeLa, THP-1, L929 | |
| Additional information | The combination of berberine and evodiamine synergistically inhibited tumor growth in vivo in MCF-7 human breast cancer xenografts. Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. | |
| PubChem ID | 442088 | |
| Additional PMIDs | 24904975 23840656 25621054 23708383 14989376 24830744 29061795 19384267 34844412 30588834 24103429 | |
| Additional sources of information | https://pfaf.org/User/Plant.aspx?LatinName=Euodia+ruticarpa | |
| Safety | NA |